Antiphospholipid Syndrome
Doruk Erkan, MD, MPH
Hospital for Special Surgery
New York, NY, United States
Disclosure(s): ACR/EULAR: Grant/Research Support (Ongoing); Aurinia: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Exagen: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Lupus Clinical Trials Consortium: Grant/Research Support (Ongoing); NIH-NIAID: Grant/Research Support (Ongoing); Up-To-Date: Royalties (Ongoing)
Jason Knight, MD, PhD
University of Michigan
Ann Arbor, MI, United States
Disclosure(s): Jazz Pharmaceuticals: Consultant (Terminated, November 9, 2022)
This session will demonstrate how to apply the new ACR/EULAR classification criteria for antiphospholipid syndrome in a case-based format, with particular emphasis on highlighting new criteria manifestations including microvascular disease. The session will also describe how these new APS criteria are being applied in ongoing clinical trials of novel therapeutics for APS, including through APS Action.
Speaker: Doruk Erkan, MD, MPH – Hospital for Special Surgery
Speaker: Jason Knight, MD, PhD – University of Michigan